EP Patent

EP0455042A1 — Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination

Assigned to ER Squibb and Sons LLC · Expires 1991-11-06 · 35y expired

What this patent protects

A pharmaceutical combination is provided which includes pravastatin and a fibric acid derivative, such as fenofibrate, gemfibrozil or bezafibrate. A method for treating dyslipidemia in non-diabetics and diabetics using the above combination is also provided.

USPTO Abstract

A pharmaceutical combination is provided which includes pravastatin and a fibric acid derivative, such as fenofibrate, gemfibrozil or bezafibrate. A method for treating dyslipidemia in non-diabetics and diabetics using the above combination is also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP0455042A1
Jurisdiction
EP
Classification
—
Expires
1991-11-06
Drug substance claim
No
Drug product claim
No
Assignee
ER Squibb and Sons LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.